Drugs / SGN-CD352A
SGN-CD352A
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02954796 | Dec 2016 → Jul 2019 | plasma cell myeloma | Seagen Inc. | Terminated | No outcome recorded Stop: Business |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SGN-CD352A | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02954796 ↗ |
| Known as | Pbd dimer adc sgn-cd352a | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297827 ↗ |
| Known as | Pbd-based anti-cd352 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297827 ↗ |
| Route | Intravenous | “SGN-CD352A will be given intravenously (into a vein; IV) every 28 days at increasing doses.” NCT02954796 ↗ |